No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long-term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS)

Drug Category : Array
Conference Category : Array
Lead Author : Steinman L, et al.
Published Date : 07/04/2025
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2025/09/AAN-2025-5-year-Ig-LLN-and-SI-FINAL.pdf
Download Text :
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top